中国伴有皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病(CADASIL)临床诊疗指南(2022版)计划书  

Chinese guideline for the diagnosis and management of CADASIL(2022 edition):a pruiocul

作　　者：中国医学科学院北京协和医学院北京协和医院神经科 中华医学会神经病学分会脑血管病学组 朱以诚[2] 姚明[2] Department of Neurology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College;Cerebrovascular Diseases Group,Neurology Branch,Chinese Medical Association;ZHU Yi-cheng

机构地区：[1]不详 [2]中国医学科学院,北京协和医学院,北京协和医院神经科,100730

出　　处：《中国现代神经疾病杂志》2023年第11期959-965,共7页Chinese Journal of Contemporary Neurology and Neurosurgery

基　　金：中国医学科学院北京协和医学院医学与健康科技创新工程(项目编号:2022-I2M-1-001);中国医学科学院北京协和医学院医学与健康科技创新工程(项目编号:2021-I2M-1-003)。

摘　　要：为进一步规范我国伴有皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病的临床诊疗决策,亟需构建基于循证医学证据的临床诊疗指南。本文参考《世界卫生组织指南制订手册》以及《中国制订/修订临床诊疗指南的指导原则(2022版)》,注册并撰写《中国伴有皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病(CADASIL)临床诊疗指南(2022版)》(以下简称指南),并遵循循证指南制订流程,制订和发布正式指南文件。指南计划书主要介绍指南制订的背景、启动与规划以及简明的制订方法,以为后续指南的成功发布奠定基础。In order to promote the clinical diagnosis,management and treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL)in China,it is necessary to construct evidence-based guidelines.The"Chinese guideline for the diagnosis and management of CADASIL(2022 edition)"will be written by using the World Health Organization(WHO)Guidelines Development Manual"and"Principles for Developing/Revising Clinical Diagnosis and Treatment Guidelines in China(2022 Edition)",and follow the evidence-based guidance development process to develop and publish formal guidance.This guide plan mainly describes the background,initiation and planning of the guide,as well as a concise development method to lay the foundation for the successful release of the subsequent guide.

关 键 词：CADASIL 诊疗指南 计划书(非MeSH词) 

分 类 号：R743[医药卫生—神经病学与精神病学]